Who are TACE plus sorafenib's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tace-plus-sorafenib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

TACE plus sorafenib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TACE plus sorafenib (TACE plus sorafenib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy (locoregional procedure + multi-kinase inhibitor). Area: Oncology.

phase 3 Combination therapy (locoregional procedure + multi-kinase inhibitor) VEGFR, PDGFR, RAF kinases (sorafenib component) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

TACE plus sorafenib (TACE plus sorafenib) — Guangxi Medical University. TACE (transarterial chemoembolization) combined with sorafenib delivers chemotherapy directly to liver tumors while sorafenib inhibits multiple tyrosine kinases to suppress tumor angiogenesis and growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TACE plus sorafenib TARGET	TACE plus sorafenib	Guangxi Medical University	phase 3	Combination therapy (locoregional procedure + multi-kinase inhibitor)	VEGFR, PDGFR, RAF kinases (sorafenib component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy (locoregional procedure + multi-kinase inhibitor) class)

Guangxi Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TACE plus sorafenib — Competitive Intelligence Brief. https://druglandscape.com/ci/tace-plus-sorafenib. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing